July 22, 2025
Vicinium, an intravesical anti-EpCAM toxin conjugate designed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer, continues to demonstrate sustained efficacy in recent Phase III clinical trials. Patients treated with Vicinium exhibited a complete response rate ranging from 40% to 52% at the three-month follow-up. Moreover, about half of these patients maintained their complete response status after one year, indicating significant durability of treatment effects. Vicinium works by selectively targeting bladder cancer cells expressing the EpCAM antigen, delivering a cytotoxic agent directly into cancer cells and sparing healthy tissue. This targeted approach has resulted in favorable safety and tolerability profiles, minimizing treatment-related side effects and enhancing patient quality of life. With limited effective therapies available post-BCG failure, Vicinium’s strong clinical performance positions it as an essential therapeutic alternative, offering clinicians and patients an effective tool to manage challenging NMIBC cases more effectively and sustainably.
Citation: Scientific Archives, 2025. Available at: https://www.scientificarchives.com
Implication: Vicinium's sustained efficacy offers patients another effective therapeutic option.